Seres Therapeutics stock analysis
Seres Therapeutics (MCRB) Stock Price & Analysis
MCRB Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 13.13M
- Enterprise Value
- CHF 51.68M
- Total Cash (Recent Filing)
- CHF 17.53M
- Total Debt (Recent Filing)
- CHF 35.77M
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- Mar 02, 2027 (Est.)
- EPS Estimate
- -0.53
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Revenue is still modest, but year-over-year growth indicates early commercial or partnership traction in the company’s microbiome therapeutics platform. If sustained, expanding revenue can improve operating leverage and provide a broader base for funding development over the next several quarters.
Improved Balance Sheet
Debt reduction and a return to positive equity represent a meaningful improvement from the company’s most stressed periods. A stronger capital structure can reduce immediate balance-sheet pressure and preserve more flexibility to advance programs, despite continued losses and elevated leverage.
SER-155 Clinical Potential
The reported investigator-sponsored results provide early clinical support for SER-155 in immune checkpoint inhibitor-related enterocolitis. A preventive therapy that helps patients remain on cancer immunotherapy could expand the addressable opportunity and strengthen the platform’s strategic relevance.
Bears Say
Deep Operating Losses
Operating losses remain dramatically larger than the current revenue base, showing that the business has not yet achieved viable operating leverage. Persistent losses can require additional financing, constrain investment choices, and make future earnings dependent on successful commercial scaling.
Persistent Cash Burn
Substantial ongoing cash consumption means operations are not funding themselves and development depends on external capital or other financing sources. This weakens financial resilience, raises the importance of successful program execution, and can limit the pace of sustainable expansion.
Elevated Leverage
Although debt has declined, leverage remains high relative to the company’s scale and is paired with deeply negative returns. This combination leaves less room to absorb setbacks, increases financial obligations while profitability is absent, and complicates funding of later-stage programs.
MCRB FAQ
What is Seres Therapeutics’s market cap?
When is Seres Therapeutics’s upcoming earnings report date?
How were Seres Therapeutics’s earnings last quarter?
Is Seres Therapeutics overvalued?
Does Seres Therapeutics pay dividends?
What is Seres Therapeutics’s EPS estimate?
What happened to Seres Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Seres Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Seres Therapeutics
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation. This candidate aims to mitigate the risk of gastrointestinal and bloodstream infections, alongside graft-versus-host disease, in vulnerable patients undergoing allogeneic hematopoietic stem cell or solid organ transplantation. Additionally, Seres Therapeutics is advancing SER-287 and SER-301, both in Phase Ib for ulcerative colitis, as well as SER-401, which targets metastatic melanoma, and SER-262, also directed at Clostridioides difficile infection. Seres maintains strategic alliances through licensing and collaboration agreements with entities such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Established in 2010, the company previously operated as Seres Health, Inc. before adopting its current name in May 2015, and it maintains its principal offices in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Richard N. Kender
- Employees
- 66
- Website
- www.serestherapeutics.com
- Address
- 101 Cambridgepark Drive, Cambridge, MA, 02140, US
Seres Therapeutics (MCRB) Earnings & Revenues
MCRB Earnings Call
Earnings Call SentimentPositive
The call highlighted significant clinical progress and financial recovery, supported by external funding and strategic cost reductions. However, the dependency on securing further capital for future studies poses a notable challenge.
View all CH:MCRB earnings summaries